@article{novn2021612,
author={S, Monga},
title={Imatinib Related Toxic Optic Neuropathy: Case Report},
journal={Neuro Ophthalmology & Visual Neuroscience},
volume={6},
number={1},
pages={4--7},
year={2021},
url={http://pubs.sciepub.com/novn/6/1/2},
issn={2572-7281},
abstract={Imatinib mesylate is a chemotherapy medication. With its use, reversible serious ocular side effects, such as optic neuropathy, retinal edema, etc. have been rarely reported. We report two contrasting presentations of imatinib induced bilateral optic neuropathy. In one case, early diagnosis and withdrawal of the drug averted significant visual loss; while in the other case, advanced bilateral optic atrophy ensued due to the late presentation. To conclude, sight threatening optic neuropathy in patients on imatinib therapy, is a possibility. It may not be necessarily reversible and warrants early discontinuation of imatinib.},
doi={10.12691/novn-6-1-2}
publisher={Science and Education Publishing}
}